Twenty-Four-Month Blood Pressure Results After Renal Denervation Using Endovascular Ultrasound

• Published in: Journal of the American Heart Association Vol. 12; no. 16; p. e030767
• Main Authors: Rosch, Sebastian, Rommel, Karl-Philipp, Blazek, Stephan, Kresoja, Karl-Patrik, Schöber, Anne, von Roeder, Maximilian, Desch, Steffen, Thiele, Holger, Lurz, Philipp, Fengler, Karl
• Format: Journal Article
• Language: English
• Published: England John Wiley and Sons Inc 15.08.2023; Wiley
• Subjects: arterial hypertension; Original Research; renal denervation; resistant hypertension; ultrasound renal denervation; arterial hypertension; ultrasound renal denervation; renal denervation; resistant hypertension
• ISSN: 2047-9980; 2047-9980
• DOI: 10.1161/JAHA.123.030767

BACKGROUND Renal denervation has proven its efficacy to lower blood pressure in comparison to sham treatment in recent randomized clinical trials. Although there is a large body of evidence for the durability and safety of radiofrequency-based renal denervation, there are a paucity of data for endovascular ultrasound-based renal denervation (uRDN). We aimed to assess the long-term efficacy and safety of uRDN in a single-center cohort of patients. METHODS AND RESULTS Data from 2 previous studies on uRDN were pooled. Ambulatory 24-hour blood pressure measurements were taken before as well as 3, 6, 12, and 24 months after treatment with uRDN. A total of 130 patients (mean age 63±9 years, 24% women) underwent uRDN. After 3, 6, 12, and 24 months, systolic mean 24-hour ambulatory blood pressure values were reduced by 10±12, 10±14, 8±15, and 10±15 mm Hg, respectively, when compared with baseline ( <0.001). Corresponding diastolic values were reduced by 6±8, 6±8, 5±9, and 6±9 mm Hg, respectively ( <0.001). Periprocedural adverse events occurred in 16 patients, and all recovered without sequelae. CONCLUSIONS In this single-center study, uRDN effectively lowered blood pressure up to 24 months after treatment.